|
1
|
Fervaha G, Foussias G, Agid O and
Remington G: Impact of primary negative symptoms on functional
outcomes in schizophrenia. Eur Psychiatry. 29:449–455.
2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Rabinowitz J, Levine SZ, Garibaldi G,
Bugarski-Kirola D, Berardo CG and Kapur S: Negative symptoms have
greater impact on functioning than positive symptoms in
schizophrenia: Analysis of CATIE data. Schizophr Res. 137:147–150.
2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Rocca P, Montemagni C, Zappia S, Piterà R,
Sigaudo M and Bogetto F: Negative symptoms and everyday functioning
in schizophrenia: A cross-sectional study in a real world-setting.
Psychiatry Res. 218:284–289. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Galderisi S, Mucci A, Buchanan RW and
Arango C: Negative symptoms of schizophrenia: New developments and
unanswered research questions. Lancet Psychiatry. 5:664–677.
2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Căpățînă O and Micluția I: Internalized
stigma as a predictor of quality of life in schizophrenia. J Evid
Based Psychother. 19:35–53. 2018.
|
|
6
|
Novick D, Montgomery W, Treuer T, Moneta
MV and Haro JM: Real-world effectiveness of antipsychotics for the
treatment of negative symptoms in patients with schizophrenia with
predominantly negative symptoms. Pharmacopsychiatry. 50:56–63.
2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kirkpatrick B, Fenton WS, Carpenter WT Jr
and Marder SR: The NIMH-MATRICS consensus statement on negative
symptoms. Schizophr Bull. 32:214–219. 2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Liemburg E, Castelein S, Stewart R, van
der Gaag M, Aleman A and Knegtering H: Genetic Risk and Outcome of
Psychosis (GROUP) Investigators. Two subdomains of negative
symptoms in psychotic disorders: Established and confirmed in two
large cohorts. J Psychiatr Res. 47:718–725. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Galderisi S, Bucci P, Mucci A, Kirkpatrick
B, Pini S, Rossi A, Vita A and Maj M: Categorical and dimensional
approaches to negative symptoms of schizophrenia: Focus on
long-term stability and functional outcome. Schizophr Res.
147:157–162. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Strauss GP, Horan WP, Kirkpatrick B,
Fischer BA, Keller WR, Miski P, Buchanan RW, Green MF and Carpenter
WT Jr: Deconstructing negative symptoms of schizophrenia:
Avolition-apathy and diminished expression clusters predict
clinical presentation and functional outcome. J Psychiatr Res.
47:783–790. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kaiser S, Lyne J, Agartz I, Clarke M,
Mørch-Johnsen L and Faerden A: Individual negative symptoms and
domains-relevance for assessment, pathomechanisms and treatment.
Schizophr Res. 186:39–45. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kring AM and Barch DM: The motivation and
pleasure dimension of negative symptoms: Neural substrates and
behavioral outputs. Eur Neuropsychopharmacol. 24:725–736.
2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Mucci A, Merlotti E, Üçok A, Aleman A and
Galderisi S: Primary and persistent negative symptoms: Concepts,
assessments and neurobiological bases. Schizophr Res. 186:19–28.
2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Haber SN and Knutson B: The reward
circuit: Linking primate anatomy and human imaging.
Neuropsychopharmacology. 35:4–26. 2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sesack S and Grace A: Cortico-basal
ganglia reward network: Microcircuitry. Neuropsychopharmacology.
35:27–47. 2010.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Juckel G, Schlagenhauf F, Koslowski M,
Wüstenberg T, Villringer A, Knutson B, Wrase J and Heinz A:
Dysfunction of ventral striatal reward prediction in schizophrenia.
Neuroimage. 29:409–416. 2006.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Strauss GP, Waltz JA and Gold JM: A review
of reward processing and motivational impairment in schizophrenia.
Schizophr Bull. 40 (Suppl 2):S107–S116. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Sescousse G, Caldú X, Segura B and Dreher
JC: Processing of primary and secondary rewards: A quantitative
meta-analysis and review of human functional neuroimaging studies.
Neurosci Biobehav Rev. 37:681–696. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Bartra O, McGuire JT and Kable JW: The
valuation system: A coordinate-based meta-analysis of BOLD fMRI
experiments examining neural correlates of subjective value.
Neuroimage. 76:412–427. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Pérez-Iglesias R, Martínez-García O,
Pardo-Garcia G, Amado J, Garcia-Unzueta M, Tabares-Seisdedos R and
Crespo-Facorro B: Course of weight gain and metabolic abnormalities
in first treated episode of psychosis: The first year is a critical
period for development of cardiovascular risk factors. Int J
Neuropsychopharmacol. 17:41–51. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
World Health Organization. ICD-10:
International statistical classification of diseases and related
health problems: 10th revision. 2nd edition. World Health
Organization, 2004. https://apps.who.int/iris/handle/10665/42980. Accessed
September 21, 2020.
|
|
22
|
Kay SR, Fiszbein A and Opler LA: The
positive and negative syndrome scale (PANSS) for schizophrenia.
Schizophr Bull. 13:261–276. 1987.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Axelrod BN, Goldman RS and Alphs LD:
Validation of the 16-item negative symptom assessment. J Psychiatr
Res. 27:253–258. 1993.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Addington D, Addington J and
Maticka-Tyndale E: Specificity of the calgary depression scale for
schizophrenics. Schizophr Res. 11:239–244. 1994.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Simpson GM and Angus JW: A rating scale
for extrapyramidal side effects. Acta Psychiatr Scand Suppl.
212:11–19. 1970.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Woods SW: Chlorpromazine equivalent doses
for the newer atypical antipsychotics. J Clin Psychiatry.
64:663–667. 2003.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Rabinowitz J, Werbeloff N, Caers I, Mandel
FS, Stauffer V, Menard F, Kinon BJ and Kapur S: Negative symptoms
in schizophrenia-the remarkable impact of inclusion definitions in
clinical trials and their consequences. Schizophr Res. 150:334–338.
2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Jolliffe IT and Cadima J: Principal
component analysis: A review and recent developments. Philos Trans
A Math Phys Eng Sci. 374(20150202)2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Strauss GP, Hong LE, Gold JM, Buchanan RW,
McMahon RP, Keller WR, Fischer BA, Catalano LT, Culbreth AJ,
Carpenter WT and Kirkpatrick B: Factor structure of the brief
negative symptom scale. Schizophr Res. 142:96–98. 2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Capatina OO and Miclutia IV: Internalized
stigma, negative symptoms and global functioning in schizophrenia.
Eur Psychiatry. 33:S574–S575. 2016.
|
|
31
|
Cather C, Barr RS and Evins AE: Smoking
and schizophrenia: Prevalence, mechanisms and implications for
treatment. Clin Schizophr Relat Psychoses. 2:70–78. 2008.
|
|
32
|
de Leon J and Diaz FJ: A meta-analysis of
worldwide studies demonstrates an association between schizophrenia
and tobacco smoking behaviors. Schizophr Res. 76:135–157.
2005.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Patkar AA, Gopalkrishnan R, Lundy A, Leone
FT, Certa KM and Weinstein SP: Relationship between tobacco smoking
and positive and negative symptoms in schizophrenia. J Nerv Ment
Dis. 190:604–610. 2002.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Krishnadas R, Jauhar S, Telfer S,
Shivashankar S and McCreadie RG: Nicotine dependence and illness
severity in schizophrenia. Br J Psychiatry. 201:306–312.
2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Drew AE and Werling LL: Nicotinic
receptor-mediated regulation of the dopamine transporter in rat
prefrontocortical slices following chronic in vivo administration
of nicotine. Schizophr Res. 65:47–55. 2003.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Kirby S, Denton A, Peterson D, Cummins E,
Dose JM and Brown R: An analysis of the rewarding and aversive
associative effects of nicotine in the neonatal quinpirole model of
schizophrenia: Underlying mechanisms and the effects of
antipsychotics. Drug Alcohol Depend. 171(e104)2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
George T: Neurobiological links between
nicotine addiction and schizophrenia. J Dual Diagn. 3:27–42.
2007.
|
|
38
|
Cook J, Spring B, McChargue D and Doran N:
Effects of anhedonia on days to relapse among smokers with a
history of depression: A brief report. Nicotine Tob Res.
12:978–982. 2010.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Olney JJ, Warlow SM, Naffziger EE and
Berridge KC: Current perspectives on incentive salience and
applications to clinical disorders. Curr Opin Behav Sci. 22:59–69.
2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Simon V, van Winkel R and De Hert M: Are
weight gain and metabolic side effects of atypical antipsychotics
dose dependent? A literature review. J Clin Psychiatry.
70:1041–1050. 2009.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Kane JM and Correll CU: The role of
clozapine in treatment-resistant schizophrenia. JAMA Psychiatry.
73:187–188. 2016.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Rummel-Kluge C, Komossa K, Schwarz S,
Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM and Leucht S:
Head-to-head comparisons of metabolic side effects of second
generation antipsychotics in the treatment of schizophrenia: A
systematic review and meta-analysis. Schizophr Res. 123:225–233.
2010.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Juutinen J, Hakko H, Meyer-Rochow VB,
Räsänen P and Timonen M: Study-70 Research Group. Body mass index
(BMI) of drug-naïve psychotic adolescents based on a population of
adolescent psychiatric inpatients. Eur Psychiatry. 23:521–526.
2008.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Salvan H, Stanculete M and Macrea R:
Frequency of sexual dysfunctions in patients with schizophrenia.
Eur Psychiatry. 22 (Suppl 1)(S138)2007.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Koga M and Nakayama K: Body weight gain
induced by a newer antipsychotic agent reversed as negative
symptoms improved. Acta Psychiatr Scand. 112:75–77. 2005.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Puia IC, Fadgyas Stanculete M, Puia A,
Hopulele-Petri A and Muresan D: Patient's perception of
weight-related stigma in a Romanian sample. JEPB. 17:147–158.
2017.
|
|
47
|
Mezquida G, Savulich G, Garcia-Rizo C,
Garcia-Portilla MP, Toll A, Garcia-Alvarez L, Bobes J, Mané A,
Bernardo M and Fernandez-Egea E: Inverse association between
negative symptoms and body mass index in chronic schizophrenia.
Schizophr Res. 192:69–74. 2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Chen SF, Hu TM, Lan TH, Chiu HJ, Sheen LY
and Loh EW: Severity of psychosis syndrome and change of metabolic
abnormality in chronic schizophrenia patients: Severe negative
syndrome may be related to a distinct lipid pathophysiology. Eur
Psychiatry. 29:167–171. 2014.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Bushe CJ, Slooff CJ, Haddad PM and
Karagianis JL: Weight change by baseline BMI from three-year
observational data: Findings from the worldwide schizophrenia
outpatient health outcomes database. J Psychopharmacol. 27:358–365.
2013.PubMed/NCBI View Article : Google Scholar
|
|
50
|
DelParigi A, Chen K, Salbe AD, Hill JO,
Wing RR, Reiman EM and Tataranni PA: Persistence of abnormal neural
responses to a meal in postobese individuals. Int J Obes Relat
Metab Disord. 28:370–377. 2004.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Matsuda M, Liu Y, Mahankali S, Pu Y,
Mahankali A, Wang J, DeFronzo RA, Fox PT and Gao JH: Altered
hypothalamic function in response to glucose ingestion in obese
humans. Diabetes. 48:1801–1806. 1999.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Rothemund Y, Preuschhof C, Bohner G,
Bauknecht HC, Klingebiel R, Flor H and Klapp BF: Differential
activation of the dorsal striatum by high-calorie visual food
stimuli in obese individuals. Neuroimage. 37:410–421.
2007.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Volkow ND, Wang GJ, Tomasi D and Baler RD:
Obesity and addiction: Neurobiological overlaps. Obes Rev. 14:2–18.
2013.PubMed/NCBI View Article : Google Scholar
|
